Indaptus Therapeutics Inc

INDP09 Dec 2024
Healthcare
$1
-0.05 (-5.21%)
Lowest Today
$1
Highest Today
$1
Today’s Open
$1
Prev. Close
$1.04
52 Week High
$3.1
52 Week Low
$0.84
To Invest in Indaptus Therapeutics Inc

Indaptus Therapeutics Inc

Healthcare
INDP09 Dec 2024
-0.05 (-5.21%)
1M
3M
6M
1Y
5Y
Low
$1
Day’s Range
High
$1
1
52 Week Low
$0.84
52-Week Range
52 Week High
$3.1
0.84
1 Day
-
1 Week
+0.97%
1 month return
-11.86%
3 month return
-28.76%
6 month return
-57.02%
1 Year return
-48%
3 Years return
-82.43%
5 Years return
-97.72%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
2.13
Vanguard Total Stock Mkt Idx Inv
1.91
Investment House LLC
0.83
Geode Capital Management, LLC
0.61
Strategy Asset Managers LLC
0.38
Fidelity Extended Market Index
0.38
Pine Valley Investments Ltd Liability Co
0.37

Market Status

Fundamentals
Market Cap
12.49 mln
PB Ratio
2.08
PE Ratio
0
Enterprise Value
5.22 mln
Total Assets
14.92 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Organisation
Indaptus Therapeutics Inc
Employees
7
Industry
Biotechnology
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities